Rite Aid Updates COVID-19 Testing Program
November 24 2020 - 8:00AM
Business Wire
Asymptomatic testing will be available at $115
for individuals 13 and older at existing Rite Aid testing sites
To continue to provide its customers with an essential service
during the pandemic, Rite Aid (NYSE: RAD) is updating its COVID-19
testing program following the end of federal funding for diagnostic
testing by the U.S. Department of Health and Human Services (HHS).
Effective December 1, 2020, no-charge testing at Rite Aid’s
existing testing sites will be replaced by testing for individuals
13 years of age and older for $115 per test (payable via cash,
credit, debit or Health Savings Account/Flexible Spending Account)
– regardless of whether the individual is symptomatic or
asymptomatic.
Additionally, in order to provide more testing access to
customers and the communities in which it does business, Rite Aid
will soon expand COVID-19 testing to up to an additional 1,000
drive-through locations.
Rite Aid partnered with the White House Coronavirus Task Force
and HHS in March to provide COVID-19 diagnostic testing. The
program evolved and scaled up in response to the growing need for
testing as the pandemic unfolded. After months of successful
partnership, HHS funding has ended, but testing at Rite Aid will
remain and be expanded.
Rite Aid’s COVID-19 testing locations utilize simple self-swab
nasal tests overseen by Rite Aid pharmacists, and operate Monday
through Friday 10 a.m. - 8 p.m. and Saturday and Sunday 10 a.m. - 5
p.m. At all testing locations, adult patients will be required to
provide government issued identification and need to pre-register
online at www.riteaid.com in order to schedule a time slot for
testing. Testing will be temporarily unavailable at Rite Aid sites
on Thanksgiving and through the weekend, and will resume on
December 1.
Previously, testing was only available to individuals 18 years
of age or older. The expanded program allows parents or legal
guardians of individuals 13-18 years of age to create Baseline
COVID-19 accounts so that they may be screened and tested. Parents
or legal guardians must provide consent for individuals under 18,
show their government issued identification and must accompany
their children to the appointment and supervise them during the
test.
“We’re proud to continue serving as an essential part of the
pandemic response in the neighborhoods we serve,” said Heyward
Donigan, president and chief executive officer, Rite Aid. “Making
testing available – and now, to a broader age range – is an
important next step in continuing to fight COVID-19.”
Currently operating 301 testing sites across 15 states, Rite Aid
has been on the front lines of the COVID-19 pandemic, partnering
with Verily and its Baseline COVID-19 Testing Program to provide
screening, scheduling and return of results to participants for
Rite Aid testing sites. BioReference Laboratories provides COVID-19
laboratory testing, while clinical oversight is provided by
PWNHealth, a national clinician network that enables safe and easy
access to diagnostic testing.
Rite Aid will continue to provide regular updates on the
company's progress with COVID-19 testing. A complete list of Rite
Aid’s COVID-19 testing sites can be found at www.riteaid.com.
About Rite Aid Corporation
Rite Aid Corporation is on the front lines of delivering
healthcare services and retail products to more than 1.6 million
Americans daily. Our pharmacists are uniquely positioned to engage
with customers and improve their health outcomes. We provide an
array of whole being health products and services for the entire
family through over 2,400 retail pharmacy locations across 18
states. Through Elixir, we provide pharmacy benefits and services
to approximately 4 million members nationwide. For more
information, www.riteaid.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201124005349/en/
Chris Savarese 717-975-5718 christopher.savarese@riteaid.com
Rite Aid (NYSE:RAD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rite Aid (NYSE:RAD)
Historical Stock Chart
From Apr 2023 to Apr 2024